Krishna Institute of Medical Sciences completed the preferential allotment of 77,02,182 warrants to its promoters and a related group entity, with the Finance and Investment Committee approving the allotment on August 19, 2026. The allotment followed receipt of the mandatory 25% upfront subscription money, amounting to ₹1,499,999,944.50. The total warrant issue is valued at approximately ₹6,000 crore, at an issue price of ₹779 per warrant.

Each warrant is convertible into one equity share of face value ₹2 within 18 months of allotment. The remaining 75% of the issue price is payable upon exercise of the conversion right.

Allotment details

The warrants were allotted to Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP. Bharas Ventures LLP is a limited liability partnership with capital contributions from promoters Dr. Bhaskara Rao Bollineni and Ms. Rajyasri Bollineni.

Impact on shareholding

The allotment increases the combined shareholding of the promoter and promoter group from 32.50% to 33.71%, assuming full conversion of the warrants into equity shares. This calculation is based on the quarterly shareholding pattern for the quarter ended June 30, 2026.

Dr. Abhinay Bollineni's individual stake rises from 0.06% (2,36,495 shares) to 0.81% (34,45,737 shares). Mr. Adwik Bollineni's stake increases from 0.01% (40,640 shares) to 0.76% (32,49,882 shares). Bharas Ventures LLP acquires a fresh stake of 0.30% (12,83,698 shares).

What the numbers show

The structure of the issue requires only a 25% upfront payment, meaning the company has secured ₹1,499,999,944.50 in cash while deferring the receipt of the remaining ₹4,499,999,835 until the warrant holders exercise their conversion rights. This deferred payment model allows the promoters to increase their voting power and economic interest without immediate full capital outlay, aligning their long-term commitment with the company's future equity expansion.

Regulatory compliance

S. R. Batliboi & Associates LLP, the statutory auditors, issued a certificate confirming compliance with Regulation 169(4) of the SEBI ICDR Regulations regarding the receipt of consideration. The disclosure was made under Regulation 30 of the SEBI LODR Regulations, 2015, following shareholder approval at the extraordinary general meeting held on July 9, 2026.

Krishna Institute of Medical Sciences Limited delivered robust top-line growth in the first quarter of FY27, with total revenue rising 36.1% year-on-year to ₹1,196 crore. The healthcare provider’s earnings call on August 4, 2026, highlighted strong operational momentum across its clusters, though net profit contracted significantly due to increased capital expenditures and interest burdens from recent expansion projects.

The company’s consolidated revenue from operations reached ₹1,180 crore, marking a 35.3% year-on-year increase and a 9.8% quarter-on-quarter rise. This growth was underpinned by substantial increases in both inpatient and outpatient volumes. Inpatient (IP) volumes climbed 26.6% year-on-year to 72,493, while outpatient (OP) volumes surged 28.5% to 6,58,617. These operational gains contributed to a 20.1% year-on-year growth in EBITDA, which stood at ₹240 crore, maintaining a margin of 20.1% compared to 20.27% in the previous year.

Despite the strong operational performance, profitability at the bottom line faced pressure. Net profit after tax (PAT) dropped 56.5% year-on-year to ₹37 crore, down from ₹85 crore in Q1FY26. This decline is attributed to higher depreciation charges and interest expenses associated with the company’s aggressive expansion strategy. Consolidated EPS for the quarter was reported at ₹104, reflecting a 2.3% quarter-on-quarter degrowth.

Financial Position and Debt Reduction

Management emphasized a strengthened balance sheet following significant capital raising initiatives. The company successfully completed a Qualified Institutional Placement (QIP), raising ₹1,500 crore, and executed a preferential allotment to promoters worth ₹600 crore. Proceeds from the QIP were primarily utilized to reduce debt, with ₹1,100 crore deployed to repay secured loans. As a result, total debt decreased from ₹3,250 crore as of March 31, 2026, to approximately ₹2,400 crore by early July 2026. Cash and cash equivalents stood at ₹505 crore as of June 30, 2026.

*Figures for Q1FY26 derived from disclosed growth percentages.

Expansion and Operational Updates

The company continued its geographic expansion, opening a new unit in Palakkad, Kerala, bringing its presence in the state to three hospitals. The Bengaluru cluster showed promising signs, with the Mahadevapura unit achieving EBITDA breakeven in less than seven months. Management expects the Electronic City unit to reach breakeven in the next one or two quarters. Additionally, the newly commissioned Kondapur facility in Telangana demonstrated strong initial traction, recording ₹45 crore in revenue during its first full month of operation in July 2026.

What the Numbers Show

The divergence between revenue growth and net profit contraction highlights the transitional phase KIMS Hospitals is undergoing. While core operations are generating strong cash flows and patient volumes are increasing, the heavy investment in greenfield projects like Kondapur and new units in Kerala and Bengaluru is temporarily suppressing bottom-line results. The strategic use of QIP proceeds to reduce debt suggests management is prioritizing balance sheet stability to fund future organic growth without excessive leverage. With mature clusters like Telangana and Andhra Pradesh continuing to deliver strong revenue and EBITDA growth, the company appears well-positioned to stabilize margins as new units ramp up over the next two to three years.